Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound could spot heart trouble before It's too late for chemo patients

NCT ID NCT01212926

Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent heart damage. Researchers measured heart function at several points over a year to see if the technique works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Echographic analysis of myocardial deformation in 2D strain (a special heart ultrasound technique)
What this could lead to
If this works, doctors could detect heart damage from chemotherapy earlier, allowing them to adjust treatment and potentially improve survival for leukemia patients.
What could go wrong
This is a small, completed study with 100 participants, so results may not apply to everyone. The technique is still experimental and not yet standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Sep 2010

Finished

May 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient female or male aged between 18 and 65 * Patients with a haematological disease and ran for a first-line chemotherapy including anthracycline * Patients with a predict cardiovascular score to 10 years below 20% or if higher, with a stress echocardiography using dobutamine, negative, for less than six months. * Patient or affiliate receiving social security * Patient informed consent and having oral and written Exclusion Criteria: * A history of chemotherapy or radiotherapy of the left hemithorax * Significant coronary artery disease: a history of angioplasty, stent, CABG, predict cardiovascular score to 10 years over 20% of stress echocardiography and dobutamine positive (three positive segments) * Left ventricular hypertrophy (diastolic septum ≥ 10 mm and diastolic posterior wall ≥ 10 mm) * One or more significant valvulopathy: Rao, RM medium or tight, IM, IT and CAI ≥ grade 2 * Secondary or primary cardiomyopathy (LVEF ≤ 50%) * Pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute leukemia Cardiotoxicity leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac toxicity Leukemia

Contacts and locations

Locations

  • Service de Cardiologie et Maladies Vasculaires, Hopital du Haut Lévêque

    Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.